
















“One for all, all for one”の重要性も学んだ．当時は英語の
原書で勉強するというのがある意味“トレンディー”で
もあったようで，解剖学は「Gray's Anatomy」，生理学は
「Guyton Physiology」， 生 化 学 は「Stryer Biochemistry, 
Lehninger Principles of Biochemistry」，薬理学は「Goodman 
and Gilman's The Pharmacological Basis of Therapeutics」，病
理学は「Robbins and Cotran Pathologic Basis of Disease」，
外科学は「Sabiston Textbook of Surgery」，小児科学は




心 身 と も に 鍛 え， か つ，The New England Journal of 




内科学第 ₂ 講座（第 ₂ 内科学教室）は₁₉₅₅年守一雄初代
教授に始まり，₁₉₇₃年に就任の金子好宏第 ₂ 代教授らが













Key words: 心血管腎臓病（Cardiovascular and renal disease），病態連関（pathologic basis of disease），
 動脈硬化（atherosclerosis），先進医療（highly advanced medical technology），




































ノックアウトマウス）を当教室に導入し₅ － ₉ ），また循環
調節系遺伝子発現調節及び受容体情報伝達系の基礎研究
を続けた₁₀－₁₈）．筑波大学では村上和雄先生から，研究を




























































































































体直接結合性低分子蛋白は，AT ₁  receptor-associated 
protein（ATRAP）とネーミングしたが，当時はATRAPの
機能的役割や病態生理学的意義が大部分未解明であり，
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“From molecules to the whole body”の考え方をベースとし
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TOWARD DEVELOPMENT OF NOVEL THERAPEUTIC APPROACH VIA FUNCTIONALLY 
SELECTIVE MODULATION OF ANGIOTENSIN RECEPTOR SIGNALING:  
FOCUS ON ANGIOTENSIN RECEPTOR-BINDING PROTEIN ATRAP
Kouichi Tamura, MD, PhD, FACP, FAHA, FJSIM, FJSH
Department of Medical Science and Cardiorenal Medicine, 
Yokohama City University Graduate School of Medicine
　Drug discovery targeting GPCRs is no longer limited to seeking agonists or antagonists to stimulate or block 
cellular responses associated with a particular receptor. GPCRs are now known to support a diversity of 
pharmacological profiles, a concept broadly referred to as functional selectivity. Therefore, if possible, functionally 
selective modulation of receptor signaling may be a safer, better tolerated, and more efficacious therapeutic strategy. 
Concerning the renin-angiotensin system, while exaggerated activation of its effector AT₁R promotes organ damage 
by BP elevation and insulin resistance via enhancement of oxidative stress and chronic inflammation, genetic 
inactivation of the renin-angiotensin system components, such as angiotensinogen, renin and AT₁R, reportedly 
results in significant hypotension and provokes renal morphological and functional alteration, even under baseline 
conditions from birth, indicating that baseline AT₁R signaling activity is indispensable for the maintenance of 
cardiovascular and renal physiology. In the course of an investigational search for a fine means to regulate AT₁R 
signaling at the local tissue sites, we have focused our analysis on the AT₁R-associated protein (ATRAP), which is 
a molecule that directly binds to the carboxyl-terminal domain of AT₁R. In contrast to the classical components of 
the renin-angiotensin system (i.e., angiotensinogen, renin and AT₁R), changes in ATRAP expression exert no evident 
effects on baseline BP and renal morphology and function in vivo, such as in ATRAP-transgenic mice and ATRAP-
deficient mice under physiological conditions. However, accumulating experimental results in these mice indicate 
that ATRAP exerts inhibitory effects on the exaggerated activation of tissue AT₁R signaling in response to 
pathological stimuli, in order to protect cardiovascular and renal tissues under pathological conditions, despite the 
lack of influence of ATRAP on physiological AT₁R signaling.
